Leo Pharma to cut 200 jobs and reorganize

Danish Leo Pharma cuts down on staff in its global operations. Around 200 positions will be cut, while 50 will be moved to Poland.

Festo Expands its Portfolio with Multilayer Manifolds

Manufacturers of medical and laboratory equipment now receive solutions from a single source

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Developing rapid diagnostics for sepsis – “Every hour counts”

Finding the right antibiotic in the right dose – with an ultra-fast analysis method. Gradientech's product solution is currently used in routine diagnostics at ...

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

Venom from the deathstalker carries radiopharmaceuticals to the brain

In order to target cancerous brain tumours with radionuclides, the problematic blood-brain barrier must first be crossed. Life Science Sweden has visited a KI r...

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

Don't miss out on this unique opportunity

ZEISS QUALITY INNOVATION SUMMIT October 22 - 24 in Berlin.

Compact and leak-tight powerhouse

Media-separated solenoid valve VYKA from Festo is virtually leak-free

Partial court victory for entrepreneur who lost his company

Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...

ZEISS presents the "Quality Innovation Summit"

A global event on the future of quality assurance.

WuXi AppTec, UK Ltd

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...

Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma

Webinar | March 13, 2024, 12 PM EST.

Save the dates: ZEISS Quality Innovation Summit, October 22-24

Embark on a journey to the future of metrology.

Life science trends 2025 – The economy

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...

Product demo with features, software and best-practices

Get interesting insights about ZEISS O-INSPECT duo in our demo recording.

Uppgifter: Sanofi tar in bud på konsumenthälsodivision

Den franska läkemedelsjätten Sanofi ska enligt uppgifter ha bett om initiala bud för sin konsumenthälsoverksamhet, som är värderad till runt 20 miljarder dollar.

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

Ingrid Lönnstedt: ”The confidence interval and its width”

Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.

Kris för hajpat genredigeringsbolag – ”Stämningen har skiftat”

Upp som en sol, ner som en pannkaka. Så kan utvecklingen för det upphaussade amerikanska genredigeringsbolaget Tome Biosciences beskrivas.